Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for CKD Prevention in NAFLD Cirrhosis
NCT05849220Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in chronic kidney disease (CKD), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Number of participants developing Chronic Kidney Disease at 1 year. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05849220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849220.